Drug in focus
NRXP drug pipeline →Preservative-Free Ketamine
◆ Mixed Named in this press release- Impact
- Phase
- Approved (ANDA)
- Time to market
- Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
- Next catalyst
- None dated
What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals, Inc. announced it will host a conference call on August 17 to discuss its Q2 2026 results.
Key Facts
- NRx Pharmaceuticals, Inc. announced it will host a conference call on August 17 to discuss its Q2 2026 results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345963 |
Track record
22 reports on NRXP
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Viewing Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers